Actelion Ltd. is a leading biopharmaceutical company focusedon the discovery, development and commercializationof innovative drugsfor diseases with significant unmet medical needs.
Jean-Paul Clozel, CEO: With Johnson & Johnson’s proposed acquisition of Actelion and the spin-out of a new R&D company, we have created unprecedented value for all of our stakeholders.
Actelion has subsidiaries in over 30 countries, covering all major pharmaceutical markets worldwide
ATLN SIX Swiss Exchange
Please note that product information contained on this website may not necessarily comply with local product information. You are solely responsible to obtain country specific documentation.
Imprint | Legal & privacy statement | Webmaster
Copyright © 2017 Actelion Pharmaceuticals Ltd
To access local information please visit one of our affiliate sites: